Preferred Stock Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards
Quotes delayed 20 minutes

Buy (3.33 out of 4)
65th percentile
(ranked higher than approx. 65% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Thursday, October 27, 12:52 AM

Slide #2. Sunesis Pharmaceuticals, Inc. Preferred Stock Offering

Company: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Date announced: 10/18/2016
Preferred Stock Offering Details: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering for clinical development of SNS-062, regulatory development of vosaroxin in Europe and other general corporate purposes.

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. QINPREZO™ (vosaroxin) is Co.'s product candidate for the treatment of acute myeloid leukemia. Co. owns worldwide development and commercialization rights to vosaroxin. Also, Co.'s development pipeline include: TAK-280, an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors; SNS-062, for treatment of B-cell malignancies and other blood cancers; and SNS-229 / SNS-510 for hematologic and solid tumor malignancies.
Open the SNSS Page at Preferred Stock Channel »

Name:  Sunesis Pharmaceuticals Inc
Sector:  Biotechnology
Number of ETFs Holding SNSS:  1 (see which ones)
Total Market Value Held by ETFs:  $10,796
Total Market Capitalization:  $58,000,000
% of Market Cap. Held by ETFs:  0.02%

Open the SNSS Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 2 of 331 | | Copyright © 2011 - 2016, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.